Table 1. Characteristics of cancer patients treated with bevacizumab included in each clinical trial of the study population.

No grade 4 toxicity was reported. CALGB: Cancer and Leukemia Group B; SD: standard deviation.

Clinical trial	CALGB 80303 (n=154)	CALGB 40503 (n=105)	CALGB 90401 (n=312)	CALGB 40502 (n=456)
Age (mean ± SD)	64.4 ± 10.5	56.9 ± 11.7	68.4 ± 8.3	57.1 ± 10.6
Male	90	0	312	0
Female	64	105	0	456
Cancer type	Advanced pancreatic cancer	Hormone receptor-positive, advanced-stage breast cancer	Metastatic castration-resistant prostate cancer	Recurrent or metastatic breast cancer
Drug treatment combined with bevacizumab	Gemcitabine	Letrozole	Docetaxel	Paclitaxel or nab-paclitaxel or ixabepilone
Hypertension grade 3 (CTCAE v 3.0)	19 (12.3%)	29 (27.6%)	21 (6.7%)	49 (10.7%)